Asset Details
Do you wish to reserve the book?
Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
Do you wish to request the book?
Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
2020
Overview
Background
COVID-19 is a highly infectious respiratory disease. No therapeutics have yet been proven effective for treating severe COVID-19.
Objectives
To determine whether human umbilical cord mesenchymal stem cell infusion may be effective and safe for the treatment of severe COVID-19.
Methods
Patients with severe COVID-19 were randomly divided into 2 groups: the standard treatment group and the standard treatment plus hUC-MSC infusion group. The incidence of progression from severe to critical illness, 28-day mortality, clinical symptom improvement, time to clinical symptom improvement, hematologic indicators including C-reactive protein, lymphocyte number, and interleukin 6, and imaging changes were observed and compared between the two groups.
Measurements and main results
The incidence of progression from severe to critical illness and the 28-day mortality rate were 0 in the hUC-MSC treatment group, while 4 patients in the control group deteriorated to critical condition and received invasive ventilation; 3 of them died, and the 28-day mortality rate was 10.34%. In the hUC-MSC treatment group, the time to clinical improvement was shorter than that in the control group. Clinical symptoms of weakness and fatigue, shortness of breath, and low oxygen saturation obviously improved beginning on the third day of stem cell infusion and reached a significant difference on day 7. CRP and IL-6 levels were significantly lower from day 3 of infusion, the time for the lymphocyte count to return to the normal range was significantly faster, and lung inflammation absorption was significantly shorter on CT imaging in the hUC-MSC group than in the control group.
Conclusions
Intravenous transplantation of hUC-MSCs is a safe and effective method that can be considered a salvage and priority treatment option for severe COVID-19.
Trial registration
Chinese Clinical Trial Registration; ChiCTR2000031494; Registered on 2 April 2020; http://
www.medresman.org
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Aged
/ Betacoronavirus - isolation & purification
/ Betacoronavirus - pathogenicity
/ Biomedical and Life Sciences
/ Biomedical Engineering and Bioengineering
/ C-Reactive Protein - metabolism
/ China
/ Coronavirus disease-19 (COVID-19)
/ Coronavirus Infections - mortality
/ Coronavirus Infections - therapy
/ Coronavirus Infections - virology
/ COVID-19
/ Female
/ Human umbilical cord mesenchymal stem cells
/ Humans
/ Male
/ Mesenchymal Stem Cell Transplantation
/ Mesenchymal Stem Cells - cytology
/ Mesenchymal Stem Cells - metabolism
/ Patients
/ Pneumonia, Viral - mortality
/ Regenerative Medicine/Tissue Engineering
/ Studies
